Bank: Novo Nordisk's US obesity drug sales are set to quadruple in three years
Novo Nordisk’s rapid growth in sales of drugs for the treatment of obesity looks set to continue. At least if you ask the major US bank JPMorgan, which predicts massive growth for Novo Nordisk’s weight-loss products, especially in the US.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.